Plus a mention of Trump, a reference to Mark Cuban, some GLP-1 hits, a 340B item, and a Wire reference
Plus a must-read STAT piece on how to think about GLP-1s
And a nice STAT explainer on 'bridge programs'
Plus a STAT story that suggests that regulatory bodies are not ready for drug development circa 2024
Plus Bernie wants to make hay around GLP-1 pricing. Bring it on, I say
And there's (even more) evidence that net prices are still falling.
And AEI provides some critical context for numbers on GLP-1 spending in Medicare
Amgen is suing Colorado, Maryland is moving forward, and commentary is piling up ...
And a survey of payers reveals some skepticism about CMS' price-setting prowess
And there is less than meets the eye in a new CBO presentation
And Orchard used an ICER assessment in setting the $4.25M price tag for its gene therapy
Plus a link to a great piece about discount rates, for you true wonks
